Press Release

Pew Applauds Enactment of User Fee Legislation, Urges Its Swift Implementation

WASHINGTON—President Barack Obama today signed into law the Food and Drug Administration Safety and Innovation Act, which supports the U.S. Food and Drug Administration’s drug and device reviews and includes other measures to benefit patients.

"By signing the FDA Safety and Innovation Act, President Obama has ensured that the FDA will have the resources and authority it needs to promote the development of safe, effective and innovative medical products that Americans need," said Allan Coukell, director of medical programs at the Pew Health Group.

"This Administration should recognize the broad, bipartisan support this bill has earned and implement it without delay."

Related Resources

The Super Bugs Causing Unmet Need and the Drugs to Fight Them

Issue Brief

Testing new antibiotics to treat highly resistant bacterial infections is especially difficult, since only a small number of patients contract such infections or meet the requirements to participate in clinical trials. Following are examples of hard-to-treat pathogens that present the greatest unmet needs today, and the types of drugs that are most likely to address them.


Payor Coverage of Medical Devices Approved Under FDA's Humanitarian Device Exemption

Other Resource
Patients with rare medical diseases sometimes lack effective medical treatments for their conditions. In these cases, the U.S. Food and Drug Administration may use a Humanitarian Device Exemption, or HDE, to bring new technologies more quickly to such patients in dire circumstances. But some health care payors—including Medicare, Medicaid, and insurance companies—do not always reimburse patients and providers for these products. More

Pew Testimony Before The President’s Council of Advisors on Science and Technology

Other Resource

The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antimicrobial resistance. Drug safety and innovation director Elizabeth Jungman testified on the need to spur the development of new antibacterial drugs.